^
    2d
    Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells. (PubMed, Sci Adv)
    Our study highlights the potent antitumor activity of low-dose decitabine-primed CAR T (dCAR T) cells in solid tumor models, a benefit previously confirmed in hematologic malignancies. This, in turn, stimulated endogenous CD8+ T cells, enhancing their antigen-spreading capacity and aiding in the clearance of abscopal antigen-negative tumors. These findings reveal the robust antigen-spreading capability of dCAR T cells, underscoring their clinical potential in addressing solid tumors with inherent antigen heterogeneity.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    decitabine
    6d
    Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CA9 (Carbonic anhydrase 9)
    |
    cyclophosphamide • fludarabine IV
    9d
    This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=55, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Mar 2026
    Enrollment open • Trial initiation date • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    17d
    CAR-T Immunotherapy Targeting CD19- ALL (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: Jul 2021 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CRLF2 (Cytokine Receptor Like Factor 2) • CD22 (CD22 Molecule) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T
    17d
    An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects with Recurrent or Progressive Grade 4 Glioma (ChiCTR2600119774)
    P=N/A, N=21, Shanghai Tongji Hospital; Shanghai Tongji Hospital
    New trial
    |
    BRAF (B-raf proto-oncogene) • CD276 (CD276 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • NTRK fusion
    20d
    Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=24, Recruiting, Sonoma Biotherapeutics, Inc. | Trial primary completion date: Mar 2026 --> Nov 2026 | Trial completion date: Mar 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    24d
    Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. (PubMed, Nat Commun)
    Previously, we showed that ex vivo priming with decitabine (DAC) enhances CAR T persistence and efficacy. Single-cell sequencing indicates that DAC priming enriches for memory-like progenitors, which maintain cytotoxic and memory signatures, and upregulates genes associated with T cell fitness and engagement of endogenous immunity. These data establish DAC-priming as a clinically feasible epigenetic reprogramming strategy enhanceing CAR T durability and efficacy, offering a generalizable paradigm for engineered cell therapies in malignant tumors.
    P1/2 data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    decitabine
    1m
    A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Calibr, a division of Scripps Research | Trial completion date: Nov 2028 --> Jun 2026 | Trial primary completion date: Nov 2028 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    2ms
    DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling. (PubMed, Signal Transduct Target Ther)
    Here, we revealed that AP-1-mediated activation was attenuated in CAR T cells impaired by tumor CD58 loss, driving a decrease in mitochondrial biogenesis, metabolic kinetic impairment, mitochondrial membrane potential loss and ROS accumulation...Our findings repositioned CD58 not merely as an immune synapse component but also a metabolic checkpoint in CAR T-cell biology, the loss of which triggers AP-1-dependent mitochondrial derangement and creates a permissive landscape for intrinsic apoptosis, which can be ameliorated by ablation of the inhibitory phosphatase DUSP6. Crucially, DUSP6 ablation represents a promising engineering target to potentiate CAR T-cell efficacy in broader applications.
    Journal
    |
    CD58 (CD58 Molecule) • DUSP6 (Dual specificity phosphatase 6)
    2ms
    Exploratory Clinical Study on the Safety of STR-P004 (clinicaltrials.gov)
    P=N/A, N=39, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Aug 2026
    Enrollment open • Trial primary completion date
    2ms
    LIBERATE: Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Quell Therapeutics Limited | Recruiting --> Active, not recruiting | Trial completion date: Mar 2040 --> Sep 2040 | Trial primary completion date: Sep 2025 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    3ms
    Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Sonoma Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed